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The antidiabetic drug metformin has been associated with reduced colorec-
tal cancer (CRC) risk and improved prognosis of CRC patients. However,
the detailed mechanisms underlying such beneficial effects remain
unknown. In this study, we aimed to evaluate metformin activity in CRC
models and unveil the underlying molecular mechanisms. We showed that
metformin inhibits CRC cell proliferation by arresting cells in the G1 phase
of the cell cycle and dramatically reduces colony formation of CRC cells.
We discovered that metformin causes a robust reduction of MYC protein
level. Through the use of luciferase assay and coincubation with either pro-
tein synthesis or proteasome inhibitors, we demonstrated that regulation of
MYC by metformin is independent of the proteasome and 30 UTR-
mediated regulation, but depends on protein synthesis. Data from poly-
some profiling and ribopuromycylation assays showed that metformin
induced widespread inhibition of protein synthesis. Repression of protein
synthesis by metformin preferentially affects cell cycle-associated proteins,
by altering signaling through the mTOR-4EBP-eIF4E and MNK1-eIF4G-
eIF4E axes. The inhibition of MYC protein synthesis may underlie met-
formin’s beneficial effects on CRC risk and prognosis.
1. Introduction
Colorectal cancer (CRC) is the third most frequent
cancer accounting for 8% of new cancer cases and the
third leading cause of cancer-related mortalities in the
United States (Siegel et al., 2017b). Moreover, the
CRC incidence and mortality rate in young adults
below 50 years of age increased by 22% and 13%,
respectively, from 2000 to 2013 in the United States
(Siegel et al., 2017a). The upward trend of CRC in
younger individuals urges discovery of novel and effec-
tive prevention strategies.
Metformin is the first-line treatment for people with
type 2 diabetes mellitus. Epidemiological studies sug-
gest metformin treatment decreases cancer risk in dia-
betic patients (Bodmer et al., 2010; Currie et al., 2009;
Abbreviations
CRC, colorectal cancer; UTR, untranslated region.
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Evans et al., 2005; Tsai et al., 2014). More recently, a
randomized phase 3 clinical trial showed that met-
formin is equally effective in preventing recurrence of
colorectal adenoma and polyps in patients without dia-
betes (Higurashi et al., 2016). The beneficial effect of
metformin in CRC is supported by experimental evi-
dence including reduction of spontaneous intestinal
polyp growth in ApcMin/+ mice and synergistic activity
with chemotherapeutic drugs in controlling CRC
growth (Tomimoto et al., 2008). Currently, multiple
clinical trials are evaluating the effect of combinations
of metformin with standard chemotherapeutics in
CRC treatment. However, the molecular mechanism
contributing to metformin’s beneficial effects in CRC
remains elusive (Thent et al., 2017).
In this report, we evaluated the effects of metformin
on CRC growth and characterized the underlying
molecular mechanisms therein. We showed that met-
formin reduces CRC cell proliferation and colony for-
mation by arresting cells in the G1 phase of the cell
cycle. We identified the MYC oncogene as a molecular
target of metformin and demonstrated robust inhibi-
tion of MYC protein synthesis by metformin without
affecting MYC mRNA levels. We further demon-
strated a broad effect of metformin on protein synthe-
sis, with a preference for cell cycle-related proteins,
and alteration of known pathways affecting protein
synthesis: AMPK-mTOR-4EBP-eIF4E and MNK1-
eIF4G-eIF4E.
2. Materials and methods
2.1. Cell lines and culture
The microsatellite instable (MSI) HCT116 and DLD1,
the microsatellite stable (MSS) HT29 and COLO320,
and HEK293 cells were obtained from the American
Type Culture Collection and validated by the Charac-
terized Cell Line Core at The University of Texas MD
Anderson Cancer Center using STR DNA fingerprint-
ing. The p53-deficient HCT116 cells (named HCT116
p53/) were a gift from Bert Vogelstein’s laboratory
(Bunz et al., 1999). Cells were maintained in Dul-
becco’s modified Eagle’s medium supplemented with
10% fetal bovine serum. All cultures were grown in
5% CO2 at 37 °C.
2.2. Reagents
The list of reagents is provided in Table S1. Briefly,
metformin hydrochloride was purchased from Abcam
(Cambridge, MA, USA); cycloheximide, AICAR, and
dorsomorphin were purchased from Sigma-Aldrich
(St. Louis, MO, USA); MG-132, MHY1485, and rapa-
mycin were purchased from EMD Millipore (Billerica,
MA, USA).
2.3. Cell viability assay
Equal numbers of cells were seeded in 96-well plates
and allowed to adhere overnight. Cells were then incu-
bated in the presence of solvent control or the indi-
cated concentrations of metformin. Cell number was
assessed using the Cell Counting Kit 8 (Dojindo
Molecular Technologies, Gaithersburg, MD, USA),
and the absorbance was measured at 450 nm by spec-
trophotometry following the manufacturer’s instruc-
tions.
2.4. Cell cycle analysis
Equal numbers of cells were seeded in 10-cm dish to
reach 60% confluence after overnight incubation. Cells
were treated with metformin or solvent control for
48 h and fixed in 70% ethanol overnight at 4 °C. The
fixed cells were stained with 50 lgmL1 propidium
iodide (PI), containing 20 lgmL1 of RNase A for
15 min, and subsequently subjected to flow cytometric
analysis.
2.5. Colony-forming assay
Cells were trypsinized and seeded in 6-well plate at 500
or 1000 cells/well. After overnight incubation, cells
were exposed to metformin or vehicle control for
10 days. The cells were fixed with absolute methanol
and stained with 1% crystal violet (Sigma-Aldrich)
(Crowley et al., 2016).
2.6. RNA isolation, cDNA synthesis, and real-time
quantitative PCR
RNA isolation, cDNA synthesis, and PCR were per-
formed as previously described (Ohtsuka et al., 2016).
Primer sequences are available in Table S2.
2.7. Protein extraction and immunoblotting
Cells were lysed in Laemmli sample buffer (Bio-Rad Lab-
oratories, Hercules, CA, USA) containing protease inhi-
bitor cocktail (Sigma) and phosphatase inhibitor cocktail
2 (Sigma). The immunoblotting analysis was performed
as previously described (Ohtsuka et al., 2016). b-Actin
was used to ensure equivalent protein loading. The
immunoblotting images were semiquantified using the
IMAGEJ software (https://imagej.nih.gov/ij/), normalized
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to the signal of b-actin, and further normalized with the
control set as 1. See Table S1 for the list of antibodies.
2.8. Protein synthesis assay
1x106 cells were seeded and left to attach overnight
before specific treatments for 24 h in glucose-free
media. Samples were further processed according to
the manufacturer’s instructions using Protein Synthesis
Assay Kit (601100, Cayman Chemical, Ann Arbor,
MI, USA). Cells were then resuspended with OPP
Working Solution for 30 min at 37 °C, washed and
stained with the 5 FAM-Azide Staining Solution, and
analyzed by flow cytometry (FC500, Beckman Coulter,
Brea, CA, USA).
2.9. Polysome profiling assay
Briefly, metformin and control-treated cells were
grown to ~70% confluence. Cells were treated with
100 lgmL1 cycloheximide at 37 °C for 15 min prior
to harvesting. Cells were lysed in lysis buffer (Pere-
boom et al., 2014), using homogenization on ice.
Lysates were cleared by centrifugation at 1200 g for
10 min, and equal OD260 units were loaded onto a
17–50% sucrose gradient. Sucrose gradients were cen-
trifuged for 2 h at 178 305 g in a Beckman SW41
rotor (Beckman Coulter, Indiana, USA) at 4 °C prior
to fractionation. Fractionation was performed on an
ISCO UV spectrophotometer and gradient fractionator
(Teledyne ISCO, Nebraska, USA). Data were collected
with LABWORKS software (Lehi, UT, USA). Postcollec-
tion data analysis was performed in Microsoft Excel
and GRAPHPAD PRISM 7 (La Jolla, CA, USA).
2.10. 30-UTR luciferase assay
The miRNA 30 UTR target clones including MYC
(NM_002467.4) 30-UTR dual-luciferase reporter
(HmiT067350-MT05) and control dual-luciferase
reporter (CmiT000001-MT05) were purchased from
GeneCopoeia (Rockville, MD, USA). Cells were
transfected with the reporter plasmid using Lipofec-
tamine 2000 (Thermo Fisher Scientific, Waltham,
MA, USA) for 24 h and then incubated with fresh
standard cell culture medium containing vehicle or
metformin for another 24 h. The cell culture medium
was collected and analyzed using Secrete-PairTM Dual
Luminescence Assay Kit (GeneCopoeia). The secreted
Gaussia Luciferase activity was normalized by the
activity of the constitutively expressed, secreted alka-
line phosphatase from the same plasmid. The normal-
ized Gaussia luciferase activity in the MYC 30-UTR
reporter was further normalized by that in the con-
trol plasmid.
2.11. Plasmid and virus generation
The lentivirus expression plasmids including pLOC-
MYC (Clone ID: PLOHS_100008545) and pLOC-RFP
(control vector) were purchased from Dharmacon
(Lafayette, CO, USA). We produced virus soup in 293
FT cells according to the instructions of the manufac-
turer and used it to induce MYC expression in CRC
cells.
2.12. Reverse-phase protein array
HT29, HCT116, HCT116 P53/, and DLD1 cells
were seeded in 100-mm dishes at 3 million cells per
dish with standard cell culture medium containing
25 mM glucose. The next day, cells were washed with
PBS and incubated in fresh glucose-free cell culture
medium in the presence of vehicle control or 2 mM
metformin for 24 h. Biological duplicates were used
for each treatment in all cell lines. Cells were lysed in
4 9 SDS sample buffer (40% glycerol, 8% SDS,
0.25 M Tris/HCl, 10% 2-mercaptoethanol, pH 6.8).
The concentration of proteins was adjusted to
1.0 lglL1 before submission to the reverse-phase
protein array (RPPA) core facility at MD Anderson
Cancer Center for array and analysis. Briefly, serial
dilutions of samples were arrayed on nitrocellulose-
coated slides and run against 302 antibodies. Spot den-
sity was determined by Array Pro, and protein concen-
tration was determined by super curve fitting. The
relative protein expression after normalization was
used for comparison between vehicle control and met-
formin treatment.
2.13. Statistical analysis
The data are presented as mean  standard deviation.
Greater than or equal to 3 independent experiments
were conducted, and significance was assessed using
Student’s t-tests. P-values <0.05 were considered statis-
tically significant. Statistical analyses were performed
with GraphPad Prism 7 (La Jolla, CA, USA).
3. Results
3.1. Metformin inhibits CRC cell growth and
colony formation
We first evaluated the effect of metformin on CRC cel-
lular growth by means of a CCK-8 assay. Treatment
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of MSI HCT116 and MSS HT29 cells with metformin
results in a dose-dependent inhibition of cell growth,
with significant differences observed at a concentration
of 5 mM metformin at both 24 h and 48 h (Fig. 1A).
We observed similar cell growth inhibition in HCT116
p53/ and DLD1 CRC cells (Fig. S1). To address
whether the inhibitory effect is due to reduced prolifer-
ation or increased cell death, we performed PI staining
for initial analysis of apoptosis and cell cycle distribu-
tion. Flow cytometric analysis revealed a clear cell
cycle arrest in G1, with a concomitant reduction of S-
phase cells (Fig. 1B). No induction of apoptosis in
sub-G1 phase cells was observed after 48-h metformin
treatment (Fig. S2). To further test the cytotoxic
effects of metformin on CRC cell growth, we per-
formed a colony formation assay to determine the
capacity of a single cell to grow into a colony. At a
concentration of 2 mM metformin, which minimally
reduced cell growth in the CCK8 proliferation assay,
metformin completely abrogated colony formation of
HCT116 and HT29 cells (Fig. 1C). The effect of met-
formin on colony formation was dose dependent
(Fig. 1D), and similar effects were observed in addi-
tional CRC cell lines (Fig. S3). Together, these data
suggest a strong inhibitory effect of metformin on
CRC cell growth.
3.2. Metformin reduces MYC protein expression
Wnt signaling is an essential factor in CRC initiation
and proliferation (Cancer Genome Atlas, 2012; Liu
et al., 2000; Phelps et al., 2009). We evaluated the
possibility that metformin inhibits CRC growth by
reducing Wnt signaling. To our surprise, we observed
an increase in Wnt activity in a TOPFLASH lucifer-
ase Wnt reporter assay, instead of the expected
decrease, following treatment with 10 mM metformin
(Fig. 2A). In concordance with the Wnt activity data,
10 mM metformin did not reduce expression of MYC
mRNA, a classical Wnt target gene, in all CRC cell
lines tested except for RKO cells (Figs 2B and S4).
However, 10 mM metformin caused almost complete
depletion of MYC protein in all tested CRC cell lines
(Figs 2B and S4). Cell growth inhibition by met-
formin is accompanied by a spindle-like morphologi-
cal shape and acidification of the media (Fig. 2C).
Cancer cells are known to enhance glycolysis in the
presence of metformin in an attempt to compensate
for energy loss following metformin inhibition of the
mitochondrial respiration chain complex (Marini
et al., 2016). To determine whether this compensation
causes the reduction of MYC protein, we examined
MYC protein during metformin treatment in either
standard culture conditions containing 25 mM of glu-
cose, or glucose-free culture conditions. The inhibitory
effect of metformin on MYC protein is also observed
under glucose-free conditions, with a clear MYC
reduction under 2 mM metformin concentration
(Fig. 2D). These data suggest that MYC reduction by
metformin is independent of glucose and is not the
consequence of enhanced glycolysis. We next tested
whether MYC reduction occurs in colony formation
assays. Because 2 mM metformin completely blocked
colony formation 10 days after cell seeding and no
material could be obtained, we examined MYC
expression in colonies formed in the presence of a
lower concentration of metformin (1 mM). Consis-
tently, we detected lower MYC protein expression in
the colonies exposed to metformin, in contrast to
those without metformin exposure (Fig. 2E).
Together, these data suggest a robust post-transcrip-
tional regulation of MYC by metformin.
3.3. Metformin blocks MYC protein synthesis
To characterize the post-transcriptional step at which
metformin reduces MYC protein, we treated cells with
cycloheximide (CHX) to block protein synthesis or
MG132 to block protein degradation (Schneider-
Poetsch et al., 2010; Tsubuki et al., 1996). We reason
that if metformin promotes MYC degradation, block-
age of protein degradation by MG132 should abro-
gate the metformin effect on MYC, while blockage of
protein synthesis with CHX should have an inverse
effect. We treated cells in standard culture conditions
with 10 mM metformin for 24 h, at which time point
MYC protein levels were reduced to half (Fig. 3A).
As expected, blockage of protein synthesis with CHX
resulted in a time-dependent reduction of MYC pro-
tein expression. However, we were unable to rescue
MYC expression with MG132 arguing against altered
MYC proteasomal degradation by metformin
(Fig. 3A,B). Consistently, metformin did not promote
the degradation of MYC protein in CHX kinetic
experiments (Fig. 3A,B). MYC phosphorylation at
threonine 58 is a well-characterized signal-promoting
MYC degradation (Sears et al., 2000; Yeh et al.,
2004). However, metformin treatment did not alter
Thr58 phosphorylation on MYC (p-MYC) (Fig. 3C).
This lack of p-MYC induction by metformin was also
observed in lysates from colony formation assays
(Fig. 3D). The above experimental data exclude the
possibility of changes in MYC turnover as a conse-
quence of metformin treatment, and suggest that met-
formin causes reduced MYC protein synthesis. Since
microRNA could block MYC protein synthesis by
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imperfect complementary binding to the 30-UTR of
the mRNA, we tested this possibility. Under condi-
tions where metformin significantly reduced MYC
protein expression, there is no significant change in
MYC 30-UTR luciferase reporter activity (Fig. 3E).
This suggests that the observed changes in MYC
Fig. 1. Metformin suppresses CRC cell growth and colony formation. (A) Metformin inhibits HCT116 and HT29 cell growth in a dose-
dependent manner. (B) Metformin arrests the HCT116 and HT29 cells at G1 phase. (C) Metformin at 2 mM completely abrogates the colony
formation ability of HCT116 and HT29 cells. (D) Metformin reduces colony formation of CRC cells in a dose-dependent fashion. The
proliferation data are presented as the means  SD of values obtained in 3 independent experiments. Student’s t-test was used to assess
significance relative to vehicle control. *P < 0.05.
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protein levels are not mediated by microRNA activity
on the 30-UTR of MYC mRNA.
It is possible that in glucose-free conditions, the regu-
latory MYC mechanisms stimulated by metformin are
different from those active under standard glucose con-
centrations. As such, we repeated our experiments in
glucose-free conditions. Similar to our data obtained
under standard glucose concentrations, we did not
observe enhanced degradation of MYC protein in glu-
cose-free conditions using CHX and MG132 assays
(Fig. 4A,B). p-MYC was not induced by metformin in
glucose-free media, similar to our data under standard
glucose concentrations (Fig. 4C). Interestingly, met-
formin reduced MYC protein expression even when
MYC was expressed from a pLOC lentiviral vector,
which contains only the MYC coding sequence without
UTRs (Fig. 4D). This finding further supports the pos-
sibility that MYC regulation by metformin is indepen-
dent of microRNA activity on the 30UTR of MYC.
Metformin is equally effective in reducing MYC levels
in COLO320 cells where MYC is amplified and
expressed at high levels (Alitalo et al., 1983; Trainer
et al., 1988) (Fig. 4E). Together, these data strongly
suggest that metformin blocks MYC protein synthesis.
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Fig. 2. Metformin reduces MYC protein expression in CRC cells. (A) Metformin increases Wnt activity as evaluated by TOPFLASH
luciferase reporter. (B) Metformin dramatically reduces MYC protein expression without affecting the MYC RNA level. (C) Metformin
promotes glycolysis, as shown by acidic medium, and change of cell morphology into spindle-like shape. (D) Metformin reduces MYC
protein expression in both standard culture condition and glucose-free condition. (E) Metformin diminishes MYC protein expression in colony
formation cells. The luciferase data in (A) are 2 independent experiments (exp1 and exp2) in quadruplicate, and data represent means  SD.
The qRT-PCR data in (B) are presented as the means  SD (HCT116, n = 2; HT29, n = 4). Student’s t-test was used to assess significance.
*P < 0.05.
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3.4. Metformin induces widespread inhibition of
protein synthesis
AMP-activated protein kinase (AMPK) and mam-
malian target of rapamycin (mTOR) signaling have
previously been demonstrated to be essential met-
formin targets that control protein synthesis (Chan
et al., 2004; Howell et al., 2017; Larsson et al., 2012).
As reported, metformin activated AMPK as reflected
by increased p-ACC (Fig. S5) (Galdieri et al., 2016)
and inhibited mTOR as shown by decreased p-4EBP1
and p-eIF4E (Fig. 5A) (Dowling et al., 2007). Similar
to metformin, treatment of CRC cells with AICAR, a
chemical AMPK activator, leads to a dramatic reduc-
tion of MYC protein (Fig. 5B). In contrast,
MHY1485, a chemical mTOR activator, partially
reversed metformin’s effect on p-4EBP1, p-eIF4E, and
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Fig. 3. Metformin blocks MYC protein synthesis in standard culture conditions. (A,B) Metformin-induced MYC reduction is neither rescued
by the proteasome inhibitor MG132, nor accelerated by the protein synthesis inhibitor CHX in HCT116 cells (A) and in HT29 cells (B). In A
and B, cells were treated with metformin for 24 h (10 mM), in the presence or absence of MG132 (10 lM). (C,D) Metformin does not
enhance the MYC phosphorylation at threonine 58 in 24 h treatment (C) or in colony formation samples (D). (E) Metformin does not reduce
luciferase activity of MYC 30UTR reporter, at the condition of causing MYC protein level changes. Cells were treated with metformin (5 mM,
10 mM) for 24 h, and culture medium was analyzed using the Secrete-PairTM Dual Luminescence Assay Kit.
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metformin reduces MYC expression in CRC cells
through AMPK activation and mTOR inhibition.
Because of the general effect of mTOR-4EBP-eIF4E
signaling in controlling protein synthesis, we tested
whether the repression of MYC by metformin repre-
sents a global blockage of protein synthesis. To this
end, we analyze the newly synthesized proteins by
employing a cell-permeable, puromycin analog O-pro-
pargyl-puromycin (OPP). The incorporation of OPP
into the C terminus of translating polypeptide chains
can be subsequently detected via copper-catalyzed click
chemistry using 5 FAM-Azide (Liu et al., 2012). Flow
cytometric analysis can then be used to detect in each
cell the total ongoing protein synthesis based on 5-
FAM fluorescence, if it is occurring. This method indi-
cated clear fluorescence in control OPP-treated sam-
ples, and as expected, low 5-FAM signal when
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Fig. 4. Metformin blocks MYC protein synthesis in glucose-free media. (A,B) Metformin-induced MYC reduction is neither rescued by the
proteasome inhibitor MG132, nor accelerated by the protein synthesis inhibitor CHX in HCT116 cells (A) and in HT29 cells (B). In A and B,
cells were treated with metformin for 24 h (2 mM), in the presence or absence of MG132 (10 lM). (C) Metformin does not enhance the
MYC phosphorylation at threonine 58. (D) Metformin reduces the overexpressed MYC protein in HT29 cells established with lentiviral MYC
plasmid lacking 50UTR and 30UTR. (E) Metformin reduces MYC protein in COLO320 cells that express high level of endogenous MYC due to
genomic amplification.
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(Fig. 5C). Metformin treatment resulted in a wide his-
togram peak with hallmarks of both the OPP control
and OPP CHX-treated samples, suggesting that a sub-
population of cells is subject to protein synthesis inhi-
bition (Figs 5C and S6A). We confirmed the
metformin effects on protein synthesis using the
ribopuromycylation assay, which detects all actively
translating ribosomes in the whole-cell population
(David et al., 2012; Schmidt et al., 2009). After met-
formin treatment, we incubated HT29 cells with puro-
mycin for 20 min to label newly synthesized proteins
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Fig. 5. Metformin induces widespread inhibition of protein synthesis. (A) Metformin abrogates the expression of p-4EBP1 and p-eIF4E at
24 h, and the effect is partially rescued by coincubation of cells with the mTOR activator MHY1485, in HCT116 cells. (B) The AMPK
activator AICAR reduces MYC expression, similar as metformin in HCT116 cells. (C) Metformin blocks protein synthesis, as shown by
reduced FITC signal, in HT29 cells stained with OPP, a puromycin analog that incorporated only to newly synthesized proteins. (D) Left
panel shows the rational of using ribopuromycylation (puromycin labeling) to monitor protein synthesis, after which the newly synthesized
protein can be detected by antibody against puromycin. Metformin strongly blocks protein synthesis, shown by reduced puromycin labeling.
AICAR induces a similar yet weaker effect. HT29 cells were treated with metformin (2.5 mM) or AICAR (0.5 mM) for 24 h, and then, the
cells were incubated with puromycin (10 lg/mL) for 20 min. Total proteins were isolated and detected by western blot using puromycin
antibody. (E) Metformin causes an increase of mRNA association with polysomes and a reduction of mRNA association with monosomes.
1864 Molecular Oncology 12 (2018) 1856–1870 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Metformin reduces MYC protein synthesis P. Shen et al.
western blot using antibodies against puromycin. In
control cells, we observed puromycin-labeled proteins
that correspond to a wide range of sizes and with high
intensity (Fig. 5D). In contrast, metformin greatly
reduced the levels of nascent puromycin-labeled pro-
teins (Fig. 5D). The AMPK activator AICAR, which
induced a weaker yet more uniform inhibition on pro-
tein synthesis (Fig. S7), reduced ribopuromycylation in
the whole-cell population to a lesser extent than met-
formin (Figs 5D and S8). Co-treatment with
MHY1485 and metformin did not significantly dimin-
ish the inhibitory effect of metformin on protein synth-
esis in either of these assays (Figs S7 and S8). This
suggests that partial rescue of mTOR signaling
(Fig. 5A), which reverses protein expression of sensi-
tive genes such as MYC, is not strong enough to
rescue global protein synthesis.
To further analyze the metformin effect on protein
synthesis, we performed polysome profiling to exam-
ine the association of mRNA with ribosomes (Chasse
et al., 2017). Polysome profiling showed a decrease in
polyribosomal mRNA, and an increase in abundance
of monoribosomal mRNA after metformin treatment.
This is a hallmark shift in polysome complexes
indicative of translational repression. In HT29 and
HCT116 cells, the polysome/monosome ratio reduced
from 1.85 (control) to 0.64 (metformin) and from
0.35 (control) to 0.17 (metformin), respectively
(Fig. 5E). Taken together, these results suggest that
metformin blocks protein synthesis, probably as a
consequence of its effect on AMPK and mTOR sig-
naling. However, it is important to note that not all
translation disappears in any of these assays upon
metformin treatment, which suggests this effect is
specific for a subset of mRNAs.
3.5. Metformin represses protein synthesis with a
preference on cell cycle-related proteins
To test whether metformin inhibits expression of a
subset of mRNAs, we sought to identify the panel of
proteins affected by metformin using RPPA in four
CRC cell lines with biological duplicates of each.
Using the criteria that proteins should change in the
same direction in both duplicates, we identified 3
upregulated proteins and 16 downregulated proteins in
all four cell lines during metformin treatment, includ-
ing the already demonstrated MYC protein (Fig. 6A
and Table S3). We selected several known important
proteins in cancer biology, including STAT3,
CDC25C, and PLK1, and validated RPPA data by
western blotting (Fig. 6B). The RNA level of these
genes is not affected by metformin (Fig. S9),
suggesting that protein synthesis is responsible for the
reduced protein expression. These data are consistent
with changes in translation of subsets of mRNAs
(Fig. 5C,D,E). Enrichment pathway analysis of the 16
downregulated proteins identified in RPPA revealed
proteins that regulate cell cycle (Fig. 6C), indicating
preferential inhibition of cell cycle-related genes by
metformin. In addition, MAP kinase-interacting pro-
tein kinase 1 (MNK1), which regulates eIF4E phos-
phorylation and is bound by eIF4G, is one of the
downregulated proteins identified by RPPA. Western
blot data showed that p-MNK1, the activate form of
MNK1, was reduced during metformin treatment
(Fig. 6D). More recently, MNK1 was reported to reg-
ulate mTORC1 signaling by promoting association of
mTORC1 with its substrates (Brown and Gromeier,
2017). Thus, reduction of MNK1 by metformin
further inhibits protein synthesis by mTORC-indepen-
dent (eIF4G-eIF4E) as well as mTORC-dependent
(mTORC1: substrate) mechanisms (Fig. 6E).
4. Discussion
Accumulating evidence supports the beneficial use of
metformin in reducing CRC risk and malignancy
(Bodmer et al., 2010; Currie et al., 2009; Evans et al.,
2005; Tsai et al., 2014), but the underlying mechanisms
remain unclear. Increased transcription of Wnt target
genes by the b-catenin/TCF complex is an essential
mechanism driving CRC carcinogenesis, progression,
and metastasis (Cancer Genome Atlas, N, 2012; Fodde
and Brabletz, 2007; Liu et al., 2000; Phelps et al.,
2009; Vermeulen et al., 2010). It is thus reasonable to
suspect that metformin might regulate Wnt signaling
to exert beneficial activities in CRC. Indeed, met-
formin was shown to reduce the size of intestinal
polyps in ApcMin/+ carcinogenesis mouse model
(Tomimoto et al., 2008). However, our data revealed
an increase, not a decrease, in Wnt activity following
metformin treatment. In contrast, MYC protein
expression was dramatically reduced by metformin,
despite a lack of change at mRNA level (He et al.,
1998). In the study with ApcMin/+ mouse model,
metformin did not alter MYC RNA expression, and
its effect on MYC protein was not tested (Tomimoto
et al., 2008). Our data suggest that the beneficial
activity of metformin is not by inhibition of MYC
transcription, but by inhibition of its translation.
Indeed, MYC is one of the most well-known oncoge-
nes, and comprehensive analysis of gene expression in
TCGA clearly revealed a pivotal role for MYC in
CRC (Cancer Genome Atlas, N, 2012; Gabay et al.,
2014).
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MYC is a desired but so far ‘undruggable’ target for
cancer treatment. Recent insights into its regulation
have led to therapeutic opportunities, as exemplified
by reducing MYC transcription using BRD4 inhibitors
(Filippakopoulos et al., 2010; Mertz et al., 2011).
Compared with these emerging drug developments,
metformin has several advantages as a MYC inhibitor:
(a) As a first-line drug treating diabetes, metformin is
safe, and its side effects are well characterized. (b)
Metformin robustly reduces the protein synthesis of
MYC, irrespective of its transcriptional status in many
CRC cell lines. In contrast, the BRD4 inhibitor JQ1
only reduces MYC in certain CRC cell types. (c) The
short half-life of MYC protein sensitizes it to protein
synthesis inhibition. (d) The oral route of metformin is
ideal for diseases of the digestive system. (e) Met-
formin’s effect on MYC is independent of glucose, and
not a mere consequence of compensated glycolysis of
cells in response to energy loss. These features make
metformin an attractive candidate for potential use
against many MYC-driven cancers.
Several previous studies reported MYC regulation
by metformin, via either microRNA regulation in
breast cancer or protein degradation in prostate cancer
(Akinyeke et al., 2013; Blandino et al., 2012). We
acknowledge that metformin is a potent drug with
multiple mechanisms, which can be context dependent.
However, under the conditions used in our experi-
ments, metformin did not affect MYC 3-UTR lucifer-
ase reporter activity. This was further substantiated by
Fig. 6. Metformin preferably represses the protein synthesis of cell cycle-related genes. (A) Venn diagram of proteins that are
downregulated by metformin (2 mM for 24 h) in four CRC cell lines identified with reverse-phase protein array (RPPA). (B) Validation of the
overlapping downregulated proteins by western blot. (C) Enrich analysis of the 16 downregulated proteins by RPPA revealed an enrichment
of proteins that regulate cell cycle. (D) Metformin reduces the expression of p-MNK1, concordant with the downregulated MNK1 by
metformin in RPPA analysis. (E) A schematic diagram presenting the proposed mechanism of metformin effects.
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the fact that metformin reduced ectopic expression of
MYC from a pLOC expression vector lacking MYC
UTR region. Furthermore, we did not observe evi-
dence of increased MYC protein degradation using
multiple strategies. These discrepancies with previous
studies may be due to different drug concentrations,
time points, and cell types. Nevertheless, considering
the well-established effect of metformin in mTOR sig-
naling and protein synthesis, it is reasonable that pro-
tein synthesis of MYC would be affected.
We found that metformin causes a broad downregu-
lation of protein synthesis only in a subpopulation of
cells, whereas CHX reduced protein synthesis in the
whole-cell population. We suspect that a subpopula-
tion of cells at a specific cell cycle stage is preferen-
tially targeted by metformin. Indeed, RPPA data
revealed an enrichment of cell cycle-related genes
including CDC25C and PLK1 in proteins downregu-
lated by metformin, echoing a previous report showing
selective translational inhibition of cell cycle regulators
such as cyclin E2 and ODC1 by metformin in breast
cancer cells (Larsson et al., 2012). However, the gene
sets regulated by metformin in the previous report are
different from the ones that we identified, and whether
these genes represent a context-dependent ‘eIF4E-sen-
sitive’ signature (Jia et al., 2012; Yanagiya et al., 2012)
remains unresolved.
We propose a mechanism of mTOR-4EBP-eIF4E
axis in regulating translation of MYC and other genes.
Interestingly, 4EBP1 has been reported to selectively
block translation of genes encoding cell cycle regula-
tors (Larsson et al., 2012). In addition, MNK1, which
regulates eIF4E phosphorylation via binding to
eIF4G, is one of the downregulated proteins identified
by RPPA in our study (Pyronnet et al., 1999; Ueda
et al., 2004). It is possible that MNK1 further regu-
lates eIF4E activity via a positive feedback loop in
controlling translational initiation. We were surprised
that this potent regulation of cap-dependent transla-
tion could have such a strong effect on subsets of
mRNA, but this selectivity has been observed before
(Yi et al., 2013). Cell cycle genes including MYC usu-
ally possess complex 50-UTR structure and are more
dependent on the unwinding activity of the DEAD-
box RNA helicase eIF4A (Koromilas et al., 1992;
Morita et al., 2015). As a key component of the eIF4F
heterotrimeric complex, eIF4E not only performs cap-
binding function, but also stimulates eIF4A helicase
activity to initiate translation (Feoktistova et al.,
2013). It is thus possible that the increased availability
of eIF4E selectively stimulates the translation of genes
that depend on the unwinding activity of eIF4A, such
as cell cycle regulators, but not that of housekeeping
genes (Feoktistova et al., 2013). MYC is a strong tran-
scriptional activator of eIF4E (Jones et al., 1996), and
thus, by targeting this eIF4E-MYC feed-forward loop
(Fig. 6E), metformin could achieve cell cycle arrest
and growth inhibition of CRC cells (Lin et al., 2009).
Additionally, other eIF4E-independent mechanisms
have recently been shown to sustain translation for
some mRNAs (Guan et al., 2017; Lee et al., 2015;
Uniacke et al., 2012). Indeed, eIF4A inhibition has
been reported as a promising strategy to reduce MYC
expression in colorectal tumors (Wiegering et al.,
2015), and the possibility of metformin directly inhibit-
ing eIF4A activity cannot be excluded.
Our study has some limitations. First, although
MYC is involved in regulating cancer metabolism, the
detailed metabolic changes caused by metformin have
not been determined in the current study. Second, we
acknowledge that inhibition of protein synthesis by
metformin affects multiple proteins, with MYC being
just one of them. Third, our findings that metformin
regulates the protein synthesis of MYC have not been
validated in mouse models. The previous work using
ApcMin/+ mice revealed AMPK activation and mTOR
inhibition, and lack of change on MYC mRNA
expression in the polyps of metformin-treated animals
(Tomimoto et al., 2008). Whether the expression of
MYC protein is reduced in such model remains to be
determined.
5. Conclusions
Our study demonstrated a mechanism of metformin
action in CRC, by blocking translation of the MYC
oncogene. This mechanism not only explains the bene-
ficial effect of metformin in CRC prevention, but also
provides additional molecular insight into why high
MYC-expressing cancer cells, which are usually ‘ad-
dicted’ to MYC, are more sensitive to metformin treat-
ment (Javeshghani et al., 2012). The use of metformin
might thus represent a combinatorial strategy to
reverse the resistance of CRC cells with high MYC
levels to chemotherapeutic drugs.
Acknowledgements
Dr. Calin is the Felix L. Haas Endowed Professor in
Basic Science. This project was supported in part by a
Department of Defense Breast Cancer Idea Award to
SJ and GAC. Work in Dr. Calin’s laboratory is sup-
ported by National Institutes of Health (NIH/NCATS)
grant UH3TR00943-01 through the NIH Common
Fund, Office of Strategic Coordination (OSC), the
NIH/NCI grant 1 R01 CA182905-01, a U54 grant
1867Molecular Oncology 12 (2018) 1856–1870 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
P. Shen et al. Metformin reduces MYC protein synthesis
#CA096297/CA096300–UPR/MDACC Partnership for
Excellence in Cancer Research 2016 Pilot Project, a
Team DOD (CA160445P1) grant, a Ladies Leukemia
League grant, a CLL Moonshot Flagship project, a
SINF 2017 grant, and the Estate of C. G. Johnson, Jr.
Functional Proteomics RPPA Core facility is sup-
ported by MD Anderson Cancer Center Support
Grant # 5 P30 CA016672-40. Peng Shen’s work was
supported by Young-Talent Oversea Research Fund
from Nanfang Hospital, Southern Medical University.
Author contributions
PS performed experiments, analyzed the data, per-
formed statistical tests, and wrote the initial draft.
LCR performed the polysome profiling assay. MC per-
formed statistical analyses. MP performed experi-
ments. EK performed experiments and revised the
manuscript. HL performed experiments, provided
supervision and assistance for writing the manuscript
and designing figures and tables, and revised the
manuscript. GAC secured funding and provided super-
vision and assistance for data analysis and interpreta-
tion and for writing the manuscript. All authors read
and approved the final manuscript.
References
Akinyeke T, Matsumura S, Wang X, Wu Y, Schalfer ED,
Saxena A, Yan W, Logan SK and Li X (2013)
Metformin targets c-MYC oncogene to prevent
prostate cancer. Carcinogenesis 34, 2823–2832.
Alitalo K, Schwab M, Lin CC, Varmus HE and Bishop
JM (1983) Homogeneously staining chromosomal
regions contain amplified copies of an abundantly
expressed cellular oncogene (c-myc) in malignant
neuroendocrine cells from a human colon carcinoma.
Proc Natl Acad Sci USA 80, 1707–1711.
Blandino G, Valerio M, Cioce M, Mori F, Casadei L,
Pulito C, Sacconi A, Biagioni F, Cortese G, Galanti S
et al. (2012) Metformin elicits anticancer effects
through the sequential modulation of DICER and c-
MYC. Nat Commun 3, 865.
Bodmer M, Meier C, Krahenbuhl S, Jick SS and Meier CR
(2010) Long-term metformin use is associated with
decreased risk of breast cancer. Diabetes Care 33,
1304–1308.
Brown MC and Gromeier M (2017) MNK controls
mTORC1: substrate association through regulation of
TELO2 binding with mTORC1. Cell Rep 18, 1444–
1457.
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y,
Dillehay L, Williams J, Lengauer C, Kinzler KW and
Vogelstein B (1999) Disruption of p53 in human cancer
cells alters the responses to therapeutic agents. J Clin
Invest 104, 263–269.
Cancer Genome Atlas, N. (2012) Comprehensive molecular
characterization of human colon and rectal cancer.
Nature 487, 330–337.
Chan AY, Soltys CL, Young ME, Proud CG and Dyck
JR (2004) Activation of AMP-activated protein
kinase inhibits protein synthesis associated with
hypertrophy in the cardiac myocyte. J Biol Chem
279, 32771–32779.
Chasse H, Boulben S, Costache V, Cormier P and Morales
J (2017) Analysis of translation using polysome
profiling. Nucleic Acids Res 45, e15.
Crowley LC, Christensen ME, Waterhouse NJ (2016)
Measuring Survival of Adherent Cells with the Colony-
Forming Assay. Cold Spring Harb Protoc 2016, pdb
prot087171.
Currie CJ, Poole CD and Gale EA (2009) The influence of
glucose-lowering therapies on cancer risk in type 2
diabetes. Diabetologia 52, 1766–1777.
David A, Dolan BP, Hickman HD, Knowlton JJ,
Clavarino G, Pierre P, Bennink JR and Yewdell JW
(2012) Nuclear translation visualized by ribosome-
bound nascent chain puromycylation. J Cell Biol 197,
45–57.
Dowling RJ, Zakikhani M, Fantus IG, Pollak M and
Sonenberg N (2007) Metformin inhibits mammalian
target of rapamycin-dependent translation initiation in
breast cancer cells. Cancer Res 67, 10804–10812.
Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR
and Morris AD (2005) Metformin and reduced risk of
cancer in diabetic patients. BMJ 330, 1304–1305.
Feoktistova K, Tuvshintogs E, Do A and Fraser CS (2013)
Human eIF4E promotes mRNA restructuring by
stimulating eIF4A helicase activity. Proc Natl Acad Sci
USA 110, 13339–13344.
Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB,
Fedorov O, Morse EM, Keates T, Hickman TT,
Felletar I et al. (2010) Selective inhibition of BET
bromodomains. Nature 468, 1067–1073.
Fodde R and Brabletz T (2007) Wnt/beta-catenin signaling
in cancer stemness and malignant behavior. Curr Opin
Cell Biol 19, 150–158.
Gabay M, Li Y, Felsher DW (2014) MYC activation is a
hallmark of cancer initiation and maintenance. Cold
Spring Harb Perspect Med 4, a014241.
Galdieri L, Gatla H, Vancurova I and Vancura A (2016)
Activation of AMP-activated protein kinase by
metformin induces protein acetylation in prostate and
ovarian cancer cells. J Biol Chem 291, 25154–25166.
Guan BJ, van Hoef V, Jobava R, Elroy-Stein O, Valasek
LS, Cargnello M, Gao XH, Krokowski D, Merrick
WC, Kimball SR et al. (2017) A Unique ISR program
determines cellular responses to chronic stress. Mol
Cell 68, 885–900 e886.
1868 Molecular Oncology 12 (2018) 1856–1870 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Metformin reduces MYC protein synthesis P. Shen et al.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da
Costa LT, Morin PJ, Vogelstein B and Kinzler KW
(1998) Identification of c-MYC as a target of the APC
pathway. Science 281, 1509–1512.
Higurashi T, Hosono K, Takahashi H, Komiya Y,
Umezawa S, Sakai E, Uchiyama T, Taniguchi L, Hata
Y, Uchiyama S et al. (2016) Metformin for
chemoprevention of metachronous colorectal adenoma
or polyps in post-polypectomy patients without
diabetes: a multicentre double-blind, placebo-
controlled, randomised phase 3 trial. Lancet Oncol 17,
475–483.
Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ,
Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ and
Manning BD (2017) Metformin inhibits hepatic
mTORC1 signaling via dose-dependent mechanisms
involving AMPK and the TSC complex. Cell Metab
25, 463–471.
Javeshghani S, Zakikhani M, Austin S, Bazile M, Blouin
MJ, Topisirovic I, St-Pierre J and Pollak MN (2012)
Carbon source and myc expression influence the
antiproliferative actions of metformin. Cancer Res 72,
6257–6267.
Jia Y, Polunovsky V, Bitterman PB and Wagner CR (2012)
Cap-dependent translation initiation factor eIF4E: an
emerging anticancer drug target. Med Res Rev 32, 786–
814.
Jones RM, Branda J, Johnston KA, Polymenis M, Gadd
M, Rustgi A, Callanan L and Schmidt EV (1996) An
essential E box in the promoter of the gene encoding
the mRNA cap-binding protein (eukaryotic initiation
factor 4E) is a target for activation by c-myc. Mol Cell
Biol 16, 4754–4764.
Koromilas AE, Lazaris-Karatzas A and Sonenberg N
(1992) mRNAs containing extensive secondary
structure in their 50 non-coding region translate
efficiently in cells overexpressing initiation factor eIF-
4E. EMBO J 11, 4153–4158.
Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ,
Pollak M and Sonenberg N (2012) Distinct perturbation
of the translatome by the antidiabetic drug metformin.
Proc Natl Acad Sci USA 109, 8977–8982.
Lee AS, Kranzusch PJ and Cate JH (2015) eIF3 targets
cell-proliferation messenger RNAs for translational
activation or repression. Nature 522, 111–114.
Lin CJ, Malina A and Pelletier J (2009) c-Myc and eIF4F
constitute a feedforward loop that regulates cell
growth: implications for anticancer therapy. Cancer
Res 69, 7491–7494.
Liu W, Dong X, Mai M, Seelan RS, Taniguchi K,
Krishnadath KK, Halling KC, Cunningham JM,
Boardman LA, Qian C et al. (2000) Mutations in
AXIN2 cause colorectal cancer with defective
mismatch repair by activating beta-catenin/TCF
signalling. Nat Genet 26, 146–147.
Liu J, Xu Y, Stoleru D and Salic A (2012) Imaging protein
synthesis in cells and tissues with an alkyne analog of
puromycin. Proc Natl Acad Sci USA 109, 413–418.
Marini C, Bianchi G, Buschiazzo A, Ravera S, Martella R,
Bottoni G, Petretto A, Emionite L, Monteverde E,
Capitanio S et al. (2016) Divergent targets of glycolysis
and oxidative phosphorylation result in additive effects
of metformin and starvation in colon and breast
cancer. Sci Rep 6, 19569.
Mertz JA, Conery AR, Bryant BM, Sandy P,
Balasubramanian S, Mele DA, Bergeron L and Sims
RJ 3rd (2011) Targeting MYC dependence in cancer by
inhibiting BET bromodomains. Proc Natl Acad Sci
USA 108, 16669–16674.
Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-
Pierre J and Topisirovic I (2015) mTOR coordinates
protein synthesis, mitochondrial activity and
proliferation. Cell Cycle 14, 473–480.
Ohtsuka M, Ling H, Ivan C, Pichler M, Matsushita D,
Goblirsch M, Stiegelbauer V, Shigeyasu K, Zhang X,
Chen M et al. (2016) H19 noncoding RNA, an
independent prognostic factor, regulates essential Rb-
E2F and CDK8-beta-catenin signaling in colorectal
cancer. EBioMedicine 13, 113–124.
Pereboom TC, Bondt A, Pallaki P, Klasson TD, Goos YJ,
Essers PB, Groot Koerkamp MJ, Gazda HT, Holstege
FC, Costa LD et al. (2014) Translation of branched-
chain aminotransferase-1 transcripts is impaired in cells
haploinsufficient for ribosomal protein genes. Exp
Hematol 42(394–403), e394.
Phelps RA, Chidester S, Dehghanizadeh S, Phelps J,
Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW
and Jones DA (2009) A two-step model for colon
adenoma initiation and progression caused by APC
loss. Cell 137, 623–634.
Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter
T and Sonenberg N (1999) Human eukaryotic
translation initiation factor 4G (eIF4G) recruits mnk1
to phosphorylate eIF4E. EMBO J 18, 270–279.
Schmidt EK, Clavarino G, Ceppi M and Pierre P (2009)
SUnSET, a nonradioactive method to monitor protein
synthesis. Nat Methods 6, 275–277.
Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick
WC, Green R, Shen B and Liu JO (2010) Inhibition of
eukaryotic translation elongation by cycloheximide and
lactimidomycin.Nat Chem Biol 6, 209–217.
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and
Nevins JR (2000) Multiple Ras-dependent
phosphorylation pathways regulate Myc protein
stability. Genes Dev 14, 2501–2514.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester
RGS, Barzi A and Jemal A (2017a) Colorectal cancer
statistics, 2017. CA Cancer J Clin 67, 177–193.
Siegel RL, Miller KD and Jemal A (2017b) Cancer
statistics, 2017. CA Cancer J Clin 67, 7–30.
1869Molecular Oncology 12 (2018) 1856–1870 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
P. Shen et al. Metformin reduces MYC protein synthesis
Thent ZC, Zaidun NH, Azmi MF, Senin MI, Haslan H
and Salehuddin R (2017) Is metformin a therapeutic
paradigm for colorectal cancer: Insight into the
molecular pathway? Curr Drug Targets 18, 734–750.
Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono
K, Takahashi H, Nakajima N, Nagashima Y, Wada
K, Nakagama H et al. (2008) Metformin suppresses
intestinal polyp growth in ApcMin/+ mice. Cancer Sci
99, 2136–2141.
Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J,
Chaikin M, Anzano M, Rieman D, Hoffstein S, Li DJ
et al. (1988) Biological characterization and oncogene
expression in human colorectal carcinoma cell lines. Int
J Cancer 41, 287–296.
Tsai MJ, Yang CJ, Kung YT, Sheu CC, Shen YT, Chang
PY, Huang MS and Chiu HC (2014) Metformin
decreases lung cancer risk in diabetic patients in a
dose-dependent manner. Lung Cancer 86, 137–143.
Tsubuki S, Saito Y, Tomioka M, Ito H and Kawashima S
(1996) Differential inhibition of calpain and
proteasome activities by peptidyl aldehydes of di-
leucine and tri-leucine. J Biochem 119, 572–576.
Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S
and Fukunaga R (2004) Mnk2 and Mnk1 are essential
for constitutive and inducible phosphorylation of
eukaryotic initiation factor 4E but not for cell growth
or development. Mol Cell Biol 24, 6539–6549.
Uniacke J, Holterman CE, Lachance G, Franovic A, Jacob
MD, Fabian MR, Payette J, Holcik M, Pause A and
Lee S (2012) An oxygen-regulated switch in the protein
synthesis machinery. Nature 486, 126–129.
Vermeulen L, De Sousa EMF, van der Heijden M,
Cameron K, de Jong JH, Borovski T, Tuynman JB,
Todaro M, Merz C, Rodermond H et al. (2010) Wnt
activity defines colon cancer stem cells and is regulated
by the microenvironment. Nat Cell Biol 12, 468–476.
Wiegering A, Uthe FW, Jamieson T, Ruoss Y,
Huttenrauch M, Kuspert M, Pfann C, Nixon C,
Herold S, Walz S et al. (2015) Targeting translation
initiation bypasses signaling crosstalk mechanisms that
maintain high MYC levels in colorectal cancer. Cancer
Discov 5, 768–781.
Yanagiya A, Suyama E, Adachi H, Svitkin YV, Aza-Blanc
P, Imataka H, Mikami S, Martineau Y, Ronai ZA and
Sonenberg N (2012) Translational homeostasis via the
mRNA cap-binding protein, eIF4E. Mol Cell 46,
847–858.
Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T,
Ivaldi G, Hahn WC, Stukenberg PT, Shenolikar S,
Uchida T et al. (2004) A signalling pathway controlling
c-Myc degradation that impacts oncogenic
transformation of human cells. Nat Cell Biol 6, 308–
318.
Yi T, Papadopoulos E, Hagner PR and Wagner G (2013)
Hypoxia-inducible factor-1alpha (HIF-1alpha)
promotes cap-dependent translation of selective
mRNAs through up-regulating initiation factor eIF4E1
in breast cancer cells under hypoxia conditions. J Biol
Chem 288, 18732–18742.
Supporting information
Additional supporting information may be found
online in the Supporting Information section at the end
of the article.
Fig. S1. Metformin inhibits the growth of HCT116
p53/ and DLD1 cells.
Fig. S2. Metformin arrests cells at G1 phase without
increasing subG1 population of HCT116 and HT29
cells.
Fig. S3. Metformin inhibits colony formation of
HCT116 p53/ and DLD1 cells in a dose-dependent
manner.
Fig. S4. Metformin reduces both the RNA and protein
levels of MYC in RKO cells.
Fig. S5. Metformin activates AMPK as reflected by
increased p-ACC expression.
Fig. S6. (A) Protein synthesis kit flow chart. (B) Puro-
mycin pull-down assay flow chart.
Fig. S7. Metformin blocks protein synthesis in HT29
cells by OPP-based protein synthesis assay.
Fig. S8. Metformin blocks protein synthesis in HT29
cells by ribopuromycylation assay.
Fig. S9. Metformin does not reduce the RNA expres-
sion level of RPPA candidate genes as shown by qRT-
PCR, at the condition that reduces their protein
expression in HCT116 and HT29 cells.
Table S1. List of reagents.
Table S2. List of primers.
Table S3. RPPA analysis identified 16 proteins that
are downregulated by metformin in all four cell lines,
including the already demonstrated MYC protein.
1870 Molecular Oncology 12 (2018) 1856–1870 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Metformin reduces MYC protein synthesis P. Shen et al.
